Quantcast

Latest Silence Therapeutics plc Stories

2010-07-14 01:00:00

LONDON, July 14 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") is pleased to announce a one-year extension of its ongoing research and development collaboration with AstraZeneca. Under the terms of the agreement, which has progressed well since being signed in July 2007, Silence and AstraZeneca are jointly collaborating in the identification and optimization of five novel siRNA therapeutic molecules addressing respiratory and oncology indications....

2010-07-07 01:00:00

LONDON, July 7 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,750,144, titled Methods and Compositions for Enhancing Efficacy and Specificity of RNA Silencing, by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of producing double stranded (RNAi) agents having decreased off-target silencing activity through certain structural modifications. The ability to...

2010-06-09 01:00:00

LONDON, June 9 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,732,593, titled Methods and Compositions For Controlling Efficacy of RNA Silencing, by the United States Patent and Trademark Office (USPTO). The issued patent, which is based on the seminal research of Phillip D. Zamore, Ph.D., Howard Hughes Medical Institute Investigator, the Gretchen Stone Cook Chair of Biomedical Sciences, and Professor of...

2010-05-26 01:00:00

LONDON, May 26 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO). The issued patent, which deepens the Company's diverse portfolio of RNA interference (RNAi) intellectual property, is broadly directed to a double-stranded short...

2010-05-11 01:00:00

LONDON, May 11 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that Philip Haworth, Ph.D., chief executive officer, will present corporate updates at two upcoming industry and financial conferences. Dr. Haworth's presentations will focus on Silence Therapeutics' comprehensive RNA interference (RNAi) therapeutics platform, broad clinical-stage pipeline and multiple ongoing collaborations with leading pharmaceutical companies. Upcoming conferences...

2010-05-05 01:00:00

LONDON, May 5 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the promotion of Jorg Kaufmann, Ph.D., to the position of vice president of research. In this new position, Dr. Kaufmann, who previously served as senior director, technologies at Silence, will play a key role in overseeing the Company's broad range of RNA interference (RNAi) research activities, including those focused on advancing Silence's novel small interfering RNA (siRNA)...

2010-04-29 01:00:00

LONDON, April 29 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces its results for the year ended 31 December 2009. On 5 January 2010, Silence merged with U.S.-based RNA interference (RNAi) therapeutic company, Intradigm Corporation, to form a leading company in the field of RNAi. The merger offers a number of strategic benefits including multiple RNAi discovery, development and delivery technologies, a broad internal and partnered product pipeline...

2010-04-28 01:00:00

LONDON, April 28 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that it will be releasing its preliminary results for the year ended 31 December 2009 on Thursday, 29 April 2010. Analyst Conference Call and Webcast: An analyst briefing call and simultaneous webcast will be held Thursday, 29 April 2010 at 2:00pm BST / 9:00am ET. The webcast can be accessed via Silence Therapeutics' website at www.silence-therapeutics.com. The conference call can...

2010-04-21 01:00:00

LONDON, April 21 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that the Company and AstraZeneca (LSE: AZN) have agreed to a one-year extension of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in March 2008, the companies are leveraging a number of Silence's proprietary lipid delivery and targeting technologies to develop new and enhanced delivery approaches for RNA...

2010-04-15 01:00:00

LONDON, April 15 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the appointment of Max Herrmann as the Company's chief financial officer and company secretary with effect from May 4, 2010. Mr. Herrmann, 44, possesses more than 20 years of biotechnology and pharmaceutical industry experience having held key management positions with leading development stage companies, as well as several investment banks. In his industry and investment banking...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'karpos', fruit.
Related